CD47 and neoplasm: Briefly, the anti‐CD47 antibody‐encapsulated CaCO3 nanoparticles (aCD47@CaCO3) incorporated fibrinogen solution and thrombin solution were sprayed and mixed at the surgical wound site to form an immunoregulatory gel in situ (Figure 14C).[164] CaCO3 nanoparticles gradually dissolved in the TME to scavenge H+ and released anti‐CD47 antibodies, promoting M1‐type macrophage activation and antitumor T cell response, thus inhibiting tumor recurrence and metastasis (Figure 14D).